Movement Alert｜Tianchen Bio-B Rises 51.05% in Regular Trading, Surging on IPO Debut with Over 4762x Oversubscription

Market Focus09:31

On June 5, Tianchen Bio-B rose 51.05% in regular trading on its first day of listing, trading at 146.7 HKD/share, with trading volume of approximately 306 million HKD, significantly above the IPO price of 96.06 HKD.

The surge was driven by the company's blockbuster IPO debut. The public offering portion received 4762.58 times oversubscription with approximately 266,400 valid applications, resulting in a one-lot winning rate of only about 2%. Prior dark-pool trading had already indicated strong demand, with shares trading at 225.8 HKD, over 135% above the offering price. The IPO raised net proceeds of approximately 1.255 billion HKD, with cornerstone investors including OrbiMed Funds, TruMed Funds, Huatai Capital, RuiYuan Fund, and Fullgoal Fund committing a combined 87 million USD.

Tianchen Bio-B is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focusing on the autonomous discovery and development of biologics for allergic and autoimmune diseases. Its core product LP-003, an anti-IgE antibody, has initiated eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179880168?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179880168","market":"us","top_or_hot":-1,"title":"Movement Alert｜Tianchen Bio-B Rises 51.05% in Regular Trading, Surging on IPO Debut with Over 4762x Oversubscription","media":"Market Focus","content":"<p><p>On June 5, Tianchen Bio-B rose 51.05% in regular trading on its first day of listing, trading at 146.7 HKD/share, with trading volume of approximately 306 million HKD, significantly above the IPO price of 96.06 HKD.</p><p>The surge was driven by the company's blockbuster IPO debut. The public offering portion received 4762.58 times oversubscription with approximately 266,400 valid applications, resulting in a one-lot winning rate of only about 2%. Prior dark-pool trading had already indicated strong demand, with shares trading at 225.8 HKD, over 135% above the offering price. The IPO raised net proceeds of approximately 1.255 billion HKD, with cornerstone investors including OrbiMed Funds, TruMed Funds, Huatai Capital, RuiYuan Fund, and Fullgoal Fund committing a combined 87 million USD.</p><p>Tianchen Bio-B is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focusing on the autonomous discovery and development of biologics for allergic and autoimmune diseases. Its core product LP-003, an anti-IgE antibody, has initiated eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Tianchen Bio-B Rises 51.05% in Regular Trading, Surging on IPO Debut with Over 4762x Oversubscription</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Tianchen Bio-B Rises 51.05% in Regular Trading, Surging on IPO Debut with Over 4762x Oversubscription\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, Tianchen Bio-B rose 51.05% in regular trading on its first day of listing, trading at 146.7 HKD/share, with trading volume of approximately 306 million HKD, significantly above the IPO price of 96.06 HKD.</p><p>The surge was driven by the company's blockbuster IPO debut. The public offering portion received 4762.58 times oversubscription with approximately 266,400 valid applications, resulting in a one-lot winning rate of only about 2%. Prior dark-pool trading had already indicated strong demand, with shares trading at 225.8 HKD, over 135% above the offering price. The IPO raised net proceeds of approximately 1.255 billion HKD, with cornerstone investors including OrbiMed Funds, TruMed Funds, Huatai Capital, RuiYuan Fund, and Fullgoal Fund committing a combined 87 million USD.</p><p>Tianchen Bio-B is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focusing on the autonomous discovery and development of biologics for allergic and autoimmune diseases. Its core product LP-003, an anti-IgE antibody, has initiated eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01779","symbol_name":"天辰生物-B","start_time":0,"source_url":"","article_id":"1179880168","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179880168","pubTimestamp":1780623086,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, Tianchen Bio-B rose 51.05% in regular trading on its first day of listing, trading at 146.7 HKD/share, with trading volume of approximately 306 million HKD, significantly above the IPO...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01779":"天辰生物-B"},"translate_title":"动静|天辰生物-B常规交易涨51.05%IPO首秀大涨超4762倍超额认购","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01779":1},"content_text":"On June 5, Tianchen Bio-B rose 51.05% in regular trading on its first day of listing, trading at 146.7 HKD/share, with trading volume of approximately 306 million HKD, significantly above the IPO price of 96.06 HKD.The surge was driven by the company's blockbuster IPO debut. The public offering portion received 4762.58 times oversubscription with approximately 266,400 valid applications, resulting in a one-lot winning rate of only about 2%. Prior dark-pool trading had already indicated strong demand, with shares trading at 225.8 HKD, over 135% above the offering price. The IPO raised net proceeds of approximately 1.255 billion HKD, with cornerstone investors including OrbiMed Funds, TruMed Funds, Huatai Capital, RuiYuan Fund, and Fullgoal Fund committing a combined 87 million USD.Tianchen Bio-B is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focusing on the autonomous discovery and development of biologics for allergic and autoimmune diseases. Its core product LP-003, an anti-IgE antibody, has initiated eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179880168","isCrawlerRequest":true}